pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·Jun 9·1 min read
save

Trump’s health-care affordability czar targets hospitals, raises concerns over suppressed alcohol study

Jun 9, 2026·read at STAT ↗RegulatoryNegative

The piece reports that the Trump administration’s health‑care affordability czar has begun scrutinizing hospitals, signaling a new push to control costs and improve price transparency.

The czar’s approach includes urging hospitals to adopt measures that could lower patient bills, though critics argue the moves may strain hospital finances and affect care delivery.

In a separate note, the article reveals that a federally funded study on alcohol consumption was not released, despite findings that even light drinking may increase the risk of serious illness, raising concerns about possible suppression of unfavorable data.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “STAT+: Trump’s health care affordability czar takes aim at hospitals”

read at STAT ↗
438 words · retrieved Jun 9
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
GILEADNOVOPFIZER
topics
Oncology2Gene Therapy (AAV)KRAS

related stories

  • Jun 9Gilead and Merck’s latest trial success and flopSTAT
  • 8h agoTScan axes 75% of workforce, prioritizes solid tumor programBioSpace
  • Jun 10STAT+: Hope for Kendall Square’s lab marketSTAT
  • Jun 8STAT+: Novo underwhelmed by drug it once fought Pfizer forSTAT
  • Jun 8STAT+: J&J spends $1 billion to enter KRAS race for cancer treatmentsSTAT